Premium
Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants
Author(s) -
Altomare Daniele,
Collij Lyduine,
Garibotto Valentina,
Poitrine Léa,
Moro Christian,
Alves Isadora Lopes,
van Maurik Ingrid S.,
Berkhof Johannes,
Scheltens Philip,
Delrieu Julien,
Molinuevo Jose Luis,
Nordberg Agneta K,
Jessen Frank,
Walker Zuzana,
Démonet JeanFrançois,
Gismondi Rossella,
Farrar Gill,
Barkhof Frederik,
Stephens Andrew W,
Frisoni Giovanni B
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.042628
Subject(s) - dementia , medicine , cognitive impairment , cognitive decline , cognition , amyloid (mycology) , disease , psychiatry , pathology
Abstract Background AMYPAD‐DPMS is the largest European, multicenter, prospective and randomized study assessing clinical utility and cost‐effectiveness of amyloid‐PET in a controlled but realistic clinical setting. In the present abstract we report preliminary results on the baseline features of the first study participants. Method A total of 900 participants (300 with subjective cognitive decline plus [SCD+], 300 with mild cognitive impairment [MCI], and 300 with dementia) will be enrolled and randomized into 3 study arms: ARM‐1, amyloid‐PET performed early in the diagnostic workup; ARM‐2, amyloid‐PET performed late in the diagnostic work‐up; and ARM‐3, amyloid‐PET performed if and when the physician chooses to. Result As of January 23 rd 2020, 617 participants (154 SCD+, 303 MCI, and 160 dementia) have been enrolled from 8 centers. Baseline features are reported in Table 1. SCD+ participants are younger than MCI ( p =0.006) and dementia ( p <0.001) participants. SCD+ are more highly educated than MCI and dementia ( p <0.001), and MCI are more highly educated that dementia ( p =0.008). As expected, worse global cognition is observed in dementia ( p <0.001) compared to MCI and SCD+, and in MCI compared to SCD+ ( p <0.001). Among those who already underwent amyloid‐PET, 34% (30/88) of SCD+, 58% (90/155) of MCI, and 74% (60/81) of dementia patients were amyloid‐positive based on visual PET scan assessment. Conclusion The socio‐demographic and cognitive features of the first 68% of AMYPAD‐DPMS participants are as expected for a memory clinic population, confirming the inclusion/exclusion criteria resulted in a representative sample. These results support the generalizability of the final study results. The end of participants’ enrolment is expected by mid‐2020.